SAN FRANCISCO—Andrew Dudum, the Chief Govt Officer of Hims & Hers Well being, Inc. (NYSE:HIMS), not too long ago reported important inventory transactions, in line with a latest SEC submitting. On December 16 and 17, Dudum offered shares totaling roughly $6.24 million. The gross sales have been executed at costs starting from $28.78 to $32.63 per share.
On December 13, Dudum acquired 176,308 shares of Class A Widespread Inventory by means of the train of inventory choices, which have been priced at $2.43 per share. Moreover, the corporate withheld 97,062 shares valued at $30.02 per share to cowl tax obligations associated to the vesting of restricted inventory items.
The transactions have been carried out beneath a pre-planned buying and selling technique, as indicated by the Rule 10b5-1 buying and selling plan adopted by Dudum in August 2024. Following these transactions, Dudum holds a direct possession of 30,710 shares, with further shares held not directly by means of the Dudum Household Neighborhood Property Belief.
Hims & Hers Well being, Inc. continues to be a key participant within the telehealth trade, offering a spread of well being and wellness options.
In different latest information, Hims & Hers Well being has seen important progress and adjustments. Morgan Stanley (NYSE:) initiated an Obese score on the corporate’s inventory, citing a robust funding alternative as a consequence of its spectacular income progress. The corporate’s Q3 gross sales noticed a 77% year-over-year enhance, surpassing $400 million. Moreover, Hims & Hers Well being forecasted This fall 2024 income between $465 million and $470 million, marking an 89% to 91% year-over-year enhance.
The corporate not too long ago introduced a partnership with Eli Lilly (NYSE:) to streamline entry to FDA-approved weight problems remedy Zepbound. Moreover, Hims & Hers Well being expanded its board of administrators, appointing Deb Autor as a brand new impartial director. BofA Securities downgraded the corporate from Purchase to Underperform, whereas TD Cowen reaffirmed its Purchase score. Piper Sandler and Needham raised their value targets, sustaining Impartial and Purchase rankings respectively.
In potential regulatory information, the corporate may gain advantage from President-elect Donald Trump’s nominee for the Meals and Drug Administration (FDA) commissioner, Dr. Martin Makary, who’s presently an govt at Sesame, a telehealth firm that sells compounded GLP-1 medication on-line. This growth might probably influence the FDA’s stance on the compounding of GLP-1 merchandise, which is essential for firms like Hims & Hers.
This text was generated with the assist of AI and reviewed by an editor. For extra data see our T&C.
